X4 Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 0.14
Market capitalization 128.08M
Operating cash flow -77.06M
ESG Scores unknown

Company description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio6.27
Working Capital-1.2
Return On Equity-1.38
Debt To Equity0.51
Fixed Asset Ratio-0.28
Fixed Interest Cover-20.69

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.31M -2.75M 1.03M 1.17M
Total Cashflows From Investing Activities 27.23M 27.23M -1.36M -615k
Net Borrowings 3.53M 481k 12.39M
Total Cash From Financing Activities 6.87M 140.66M 12.39M 74.25M
Change To Operating Activities 1.83M -484k -5.09M -2.66M
Issuance Of Stock 7k 140.18M 561k 76.25M
Net Income -33.28M -52.81M -62.13M -88.7M
Change In Cash -18.55M 119.59M -47.38M 2.41M
Effect Of Exchange Rate -250k -250k 402k -319k
Total Cash From Operating Activities -25.42M -48.05M -58.82M -70.91M
Depreciation 103k 103k 351k 499k
Change To Account Receivables
Other Cashflows From Financing Activities -277k -277k -277k
Change To Netincome 4.47M 7.19M 6.49M 18.03M
Capital Expenditures -174k -174k -1.36M -615k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 20.35M 30.16M 41.93M 50.65M
Income Before Tax -33.28M -52.81M -61.98M -88.68M
Net Income -33.28M -52.81M -62.13M -88.7M
Selling General Administrative 8.74M 17.64M 20.94M 24.7M
Gross Profit 3M
Ebit -29.09M -47.8M -59.87M -75.35M
Operating Income -29.09M -47.8M -59.87M -75.35M
Interest Expense -720k -2.15M -2.69M -3.64M
Income Tax Expense 148k 17k
Total Revenue 3M
Cost Of Revenue
Total Other Income ExpenseNet -4.2M -5M -2.11M -13.33M
Net Income From Continuing Ops -33.28M -52.81M -62.13M -88.7M
Net Income Applicable To Common Shares -36.31M -53.4M -62.13M -102.64M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 17.41M 31.48M 50.07M 52.76M
Total Stockholder Equity -77.09M 129.22M 72.8M 64.41M
Other Current Liabilities
Total Assets 9.94M 160.7M 122.87M 117.18M
Common Stock 16k 16k 28k
Other Current Assets 264k
Retained Earnings -79.24M -132.04M -194.18M -282.87M
Treasury Stock -119k -119k -119k
Cash 8.13M 126.18M 78.71M 81.79M
Total Current Liabilities 7.91M 9.45M 11.95M 14.02M
Other Stockholder Equity -119k -119k -119k
Property, Plant, and Equipment 241k 2.36M 9.2M 10.22M
Total Current Assets 9.34M 129.28M 83.31M 87.88M
Net Tangible Assets -77.09M 102.11M 45.69M 47.06M
Net Receivables 2M 917k 747k
Accounts Payable 2.97M 2.09M 3.14M 4.28M


Insider Transactions

Here are the insider transactions of stock shares related to X4 Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
MOSTAFA ADAM S.Sale at price 1.16 per share.D2022-08-17Chief Financial Officer10.83k
MEISNER DEREK MSale at price 1.16 per share.D2022-08-17Officer8.33k
RAGAN PAULASale at price 1.16 per share.D2022-08-17Chief Executive Officer13.45k
DIBIASE MARYSale at price 1.16 per share.D2022-08-17Chief Operating Officer1.71k
MOSTAFA ADAM S.Sale at price 0.96 per share.D2022-06-30Chief Financial Officer2.64k
DIBIASE MARYSale at price 0.96 per share.D2022-06-30Chief Operating Officer1.58k
MOSTAFA ADAM S.Sale at price 1.07 per share.D2022-06-24Chief Financial Officer5.42k
MEISNER DEREK MSale at price 1.07 per share.D2022-06-24Officer4.17k
RAGAN PAULASale at price 1.07 per share.D2022-06-24Chief Executive Officer6.72k
DIBIASE MARYSale at price 1.07 per share.D2022-06-24Chief Operating Officer856
MOSTAFA ADAM S.Sale at price 1.07 per share.D2022-06-16Chief Financial Officer5.42k
MEISNER DEREK MSale at price 1.07 per share.D2022-06-16Officer4.17k
RAGAN PAULASale at price 1.07 per share.D2022-06-16Chief Executive Officer6.72k
DIBIASE MARYSale at price 1.07 per share.D2022-06-16Chief Operating Officer856
ALISKI WILLIAM EStock Award(Grant) at price 0.00 per share.D2022-06-06Director6.67k
WYZGA MICHAEL SStock Award(Grant) at price 0.00 per share.D2022-06-06Director6.67k
MCGIRR DAVID W JStock Award(Grant) at price 0.00 per share.D2022-06-06Director6.67k
LAWTON ALISON FRANCESStock Award(Grant) at price 0.00 per share.D2022-06-06Director6.67k
STEWART MURRAYStock Award(Grant) at price 0.00 per share.D2022-06-06Director6.67k
BRIDGER GARY JStock Award(Grant) at price 0.00 per share.D2022-06-06Director6.67k
DE CRAECKER FRANCOISEStock Award(Grant) at price 0.00 per share.D2022-06-06Director6.67k
RAGAN PAULASale at price 1.21 per share.D2022-06-03Chief Executive Officer6.29k
MOSTAFA ADAM S.Stock Award(Grant) at price 0.00 per share.D2022-03-01Chief Financial Officer105k
MEISNER DEREK MStock Award(Grant) at price 0.00 per share.D2022-03-01Officer105k
RAGAN PAULAStock Award(Grant) at price 0.00 per share.D2022-03-01Chief Executive Officer220.79k
CADAVID DIEGOStock Award(Grant) at price 0.00 per share.D2022-03-01Officer97k
TAVERAS ARTHUR PHDStock Award(Grant) at price 0.00 per share.D2022-03-01Officer97k
DIBIASE MARYStock Award(Grant) at price 0.00 per share.D2022-03-01Chief Operating Officer105k
MOSTAFA ADAM S.Sale at price 1.56 per share.D2022-02-11Chief Financial Officer27.72k
MEISNER DEREK MSale at price 1.56 per share.D2022-02-11Officer15.91k
RAGAN PAULASale at price 1.56 per share.D2022-02-11Chief Executive Officer21.7k
CADAVID DIEGOSale at price 1.56 per share.D2022-02-11Officer928
DIBIASE MARYSale at price 1.56 per share.D2022-02-11Chief Operating Officer12.54k
DIBIASE MARYStock Award(Grant) at price 0.00 per share.D2021-09-08Chief Operating Officer27k
MOSTAFA ADAM S.Sale at price 5.10 per share.D2021-08-17Chief Financial Officer10.83k
MEISNER DEREK MSale at price 5.10 per share.D2021-08-17General Counsel8.33k
RAGAN PAULASale at price 5.10 per share.D2021-08-17Chief Executive Officer13.45k
RAGAN PAULASale at price 5.78 per share.D2021-07-15Chief Executive Officer13.45k
MOSTAFA ADAM S.Sale at price 6.64 per share.D2021-06-30Chief Financial Officer2.64k
MOSTAFA ADAM S.Sale at price 7.01 per share.D2021-06-24Chief Financial Officer5.42k
MEISNER DEREK MSale at price 7.00 per share.D2021-06-24General Counsel4.17k
MOSTAFA ADAM S.Stock Award(Grant) at price 0.00 per share.D2021-06-23Chief Financial Officer16.25k
MEISNER DEREK MStock Award(Grant) at price 0.00 per share.D2021-06-23General Counsel12.5k
RAGAN PAULAStock Award(Grant) at price 0.00 per share.D2021-06-23Chief Executive Officer44.83k
MOSTAFA ADAM S.Stock Award(Grant) at price 0.00 per share.D2021-06-15Chief Financial Officer16.25k
MOSTAFA ADAM S.Sale at price 7.84 per share.D2021-06-15Chief Financial Officer5.42k
MEISNER DEREK MStock Award(Grant) at price 0.00 per share.D2021-06-15General Counsel12.5k
MEISNER DEREK MSale at price 7.84 per share.D2021-06-15General Counsel4.17k
RAGAN PAULAStock Award(Grant) at price 0.00 per share.D2021-06-15Chief Executive Officer44.83k
RAGAN PAULASale at price 9.50 per share.D2021-06-02Chief Executive Officer2.4k
RAGAN PAULASale at price 9.41 per share.D2021-06-01Chief Executive Officer4.1k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to X4 Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on X4 Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to X4 Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on X4 Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to X4 Pharmaceuticals Inc:

X4 Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -46.85% on the backtest period.

Performance at glance

Performance

-46.85 %

Latent gain

-927.68 $

Invested capital

1980.28 $

Annualized return

-11.6 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on X4 Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to X4 Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on X4 Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on X4 Pharmaceuticals Inc:

X4 Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give -44.08% of return on X4 Pharmaceuticals Inc. That represents -2310.05$ of latent gain with 5240.71$ of employed capital.
  • The second momentum investment strategy would give -42.79% of return on X4 Pharmaceuticals Inc. That represents -1263.95$ of latent gain with 2953.65$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-44.08 %

Latent gain

-2310.05 $

Invested capital

5240.71 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-42.79 %

Latent gain

-1263.95 $

Invested capital

2953.65 $

Annualized return

-12.02 %

Momentum equity curve on X4 Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to X4 Pharmaceuticals Inc:

X4 Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by X4 Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on X4 Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on X4 Pharmaceuticals Inc since the beginning:

X4 Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on X4 Pharmaceuticals Inc

Buy the dip entry openings on X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc

The performance achieved by the robo-advisor on X4 Pharmaceuticals Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows X4 Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of X4 Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to X4 Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to X4 Pharmaceuticals Inc:

X4 Pharmaceuticals Inc

Note: the dividends potentially given by X4 Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on X4 Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on X4 Pharmaceuticals Inc:

X4 Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on X4 Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to X4 Pharmaceuticals Inc.

Equity curve comparison on X4 Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

X4 Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc investment comparison

Performance comparison on X4 Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -46.85% -927.68$ 1980.28$ -11.6%
Momentum 1 quarter -44.08% -2310.05$ 5240.71$ -11.6%
Momentum 2 quarters -42.79% -1263.95$ 2953.65$ -12.02%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-11.6 %

Momentum 1Q

-12.02 %

Momentum 2Q

-12.02 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with X4 Pharmaceuticals Inc:

Positive correlations

Most correlated stocks this year

  • X4 Pharmaceuticals Inc

  • Most correlated stocks last 3 months

  • STARLIGHT CUL
  • GOME RETAIL
  • X4 Pharmaceuticals Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • LH GROUP
  • SINOFERT
  • SHENZHENEXPRESS

  • Note: The algorithm computes the probability of correlation between X4 Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of X4 Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name X4 Pharmaceuticals Inc
    Country United States
    City Boston
    Address 61 North Beacon Street
    Phone 857 529 8300
    Website www.x4pharma.com
    FullTime employees 83
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker XFOR
    Market www.nasdaq.com

    X4 Pharmaceuticals Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown